UOC
URGN icon

UBS O'Connor’s UroGen Pharma URGN Stock Holding History

UBS O'Connor’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-16,250
Closed -$700K – 139
2018
Q4 		$700K Sell
16,250
-6,409
-28% -$288K 0.03% 181
2018
Q3 		$1.07M Hold
22,659
– – 0.02% 200
2018
Q2 		$1.13M Buy
+22,659
New +$1.32M 0.02% 202

Other funds holding URGN

MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
HCM
Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS O'Connor's URGN Position: Q1 2019 in Review

UBS O'Connor sold out of UroGen Pharma (URGN) in Q1 2019, closing a stake of 16,250 shares — an estimated $700K sold.

UBS O'Connor first reported a position in URGN in Q2 2018 and held it in 3 quarters. The position peaked at $1.13M in Q2 2018. 74 funds tracked by Wall St. Rank hold URGN as of Q1 2019.

  • UBS O'Connor reported no remaining UroGen Pharma position as of Q1 2019 after selling out during the quarter.
  • UBS O'Connor sold 16,250 UroGen Pharma shares in Q1 2019, an estimated $700K.
  • UBS O'Connor first reported a position in UroGen Pharma in Q2 2018 and held it in 3 quarters.
  • UBS O'Connor's UroGen Pharma position peaked at $1.13M in Q2 2018.
  • 74 funds tracked by Wall St. Rank held UroGen Pharma as of Q1 2019.

Based on UBS O'Connor's 13F filing for Q1 2019, filed 13 May 2019.